FG-2216

• Description :

  FG-2216 (IOX3) is a potent and orally active inhibitor of HIF prolyl hydroxylase-2 (PHD2), with an IC50 of 3.9 μM. FG-2216 induces robust erythropoietin and modest fetal hemoglobin in vivo[1][2][3].

• Product Name Alternative :

  IOX3; YM311

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  HIF/HIF Prolyl-Hydroxylase

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Field of Research :

  Metabolic Disease

• Assay Protocol :

  https://www.medchemexpress.com/FG-2216.html

• Purity :

  99.46

• Solubility :

  DMSO : 50 mg/mL (ultrasonic)

• Smiles :

  O=C(O)CNC(C1=C(O)C2=C(C(Cl)=N1)C=CC=C2)=O

• Molecular Formula :

  C12H9ClN2O4

• Molecular Weight :

  280.66

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Hong YR, et al. [ (4-Hydroxyl-benzo[4,5]thieno[3,2-c]pyridine-3-carbonyl) -amino]-acetic acid derivatives; HIF prolyl 4-hydroxylase inhibitors as oral erythropoietin secretagogues. Bioorg Med Chem Lett. 2013 Nov 1;23 (21) :5953-7.|[2]Hsieh MM, et al. HIF prolyl hydroxylase inhibition results in endogenous erythropoietin induction, erythrocytosis, and modest fetal hemoglobin expression in rhesus macaques. Blood. 2007 Sep 15;110 (6) :2140-7.|[3]Bernhardt WM, et, al. Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J Am Soc Nephrol. 2010 Dec;21 (12) :2151-6.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 2

• CAS Number :

  [223387-75-5]